Consequently, a genomic amplification at 22q11 (and additionally at 9q34) in K-562 cells targets both TBX1 and fusion gene BCR::ABL1 [21], highlighting their pathogenic function in CML. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.